+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cymbalta (duloxetine) Drug Overview 2019

  • ID: 4846129
  • Report
  • March 2019
  • Region: Global
  • 25 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since accrued a number of additional indications for Cymbalta, including diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia in the US, and most recently, chronic musculoskeletal pain. The drug is also marketed for the treatment of women with moderate to severe stress urinary incontinence in Europe under the brand name Yentreve.

Cymbalta was formerly marketed by Boehringer Ingelheim in a number of European countries under the brand name Xeristar, although Eli Lilly has since reacquired exclusive rights to develop and market duloxetine. In Japan – where Cymbalta was not launched until April 2010 – the drug is jointly marketed by Shionogi and Eli Lilly for the treatment of depression and depressive symptoms.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
  • Drug Overview
  • Product Profiles
  • Cymbalta: Depression
  • Cymbalta: Neuropathic pain
LIST OF FIGURES
Figure 1: The author's drug assessment summary of Cymbalta for depression
Figure 2: The author's drug assessment summary of Cymbalta for depression
Figure 3: Cymbalta sales for depression across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Cymbalta for neuropathic pain – SWOT analysis
Figure 5: The author's drug assessment summary of Cymbalta for neuropathic pain
Figure 6: The author's drug assessment summary of Cymbalta for neuropathic pain
Figure 7: Cymbalta sales for neuropathic pain disease across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Cymbalta drug profile
Table 2: Approval history of Cymbalta for depression in the US, Japan, and five major EU markets
Table 3: Late-phase trials of Cymbalta for depression
Table 4: Cymbalta ongoing Phase III trials in depression
Table 5: Cymbalta for depression – SWOT analysis
Table 6: Cymbalta drug profile
Table 7: Cymbalta Phase III data in neuropathic pain syndromes
Table 8: Cymbalta sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll